Skip to main content

Advertisement

Table 1 Baseline description of the D2C cohort

From: Cancer incidence in type 2 diabetes patients - first results from a feasibility study of the D2C cohort

  Men Women
N 12 650 47,3% 14 092 52,7%
Median follow-up time (years) 3.54 [0.3 - 5.8] 3.79 [0.2 - 5.8]
Mean Age (years) 62.6 [40-79] 65.2 [40-79]
Median BMI (kg/m2) 29.7 [16.3 - 44.9] 31.0 [16.2 - 44.9]
Current smokers 2934 23.2% 1659 11.8%
Year of enrolment in DMP     
   2003/2004 5 845 46.2% 6 838 48.5%
   2005/2006 3 148 24.9% 3 407 24.2%
   2007/2008 3 657 28.9% 3 847 27.3%
Anti-diabetic medication     
   No medication 3 041 24.0% 3 465 24.6%
   Metformin only 4 580 36.2% 5 064 35.9%
   Any other oral antidiabetic drug 1 782 14.1% 1 868 13.3%
   Human insulin (alone or with metformin) 2 558 20.2% 3 018 21.4%
   Insulin Analogues (alone or with insulin and/or metformin) 690 5.5% 677 4.8%